# 2024-04-15--中药-马应龙-百年肛肠品牌开拓边界，结构优化未来可期_page5_表1分业务收入及毛利率

| 单位：亿元 | 2023A | 2024E | 2025E | 2026E |
| --- | --- | --- | --- | --- |
| 医药工业 | 收入 | -18.3 | 20.7 | 23.9 | 27.8 |
| 增速 | -11.5% | 13.0% | 15.4% | 16.2% |
| 毛利率 | 64.6% | 63.8% | 63.5% | 63.3% |
| 医药商业 | 收入 | 10.9 | 9.2 | 8.3 | 7.7 |
| 增速 | -19.7% | -15.0% | -10.0% | -8.0% |
| 毛利 率 | 6.2% | 6.1% | 6.1% | 6.1% |
| 医疗服务 | 收入 | 3.4 | 4.0 | 4.5 | 4.9 |
| 增速 | 33.3% | 15.0% | 13.0% | 10.0% |
| 毛利润率 | 13.7% | 13.5% | 13.6% | 13.7% |
| 内部抵消 | 收入 | -1.8 | -1.5 | -1.7 | -1.8 |
| 总收入 | 收入 | -31.4 | -32.4 | -35.0 | -38.6 |
| 增速 | -11.2% | 3.4% | 8.0% | 10.1% |
| 毛利润 率 | 40.5% | 43.9% | 46.2% | 48.5% |